Osteopontin is dispensable for protection against high load systemic fungal infection

International Immunopharmacology

Volumn 8, Issue 10, 2008, Pages 1441-1448

  Sato, Ikuko ^a   Yamamoto, Nobuchika ^a   Rittling, Susan R ^b   Denhardt, David T ^b   Hino, Motohiro ^a   Morimoro, Junko ^c   Sakai, Fumihiko ^a   Fujie, Akihiko ^a   Uede, Toshimitsu ^c  

^a ASTELLAS PHARMA INC   (Japan)

^b RUTGERS UNIVERSITY   (United States)

^c HOKKAIDO UNIVERSITY   (Japan)

Author keywords

Anti osteopontin antibody; Candida albicans; Infection; Osteopontin

Indexed keywords

CYTOKINE; EPITOPE; IMMUNOGLOBULIN G ANTIBODY; NEUTRALIZING ANTIBODY; OSTEOPONTIN; OSTEOPONTIN ANTIBODY; RECOMBINANT M5 ANTIBODY; THROMBIN; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; CANDIDA ALBICANS; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG BINDING; FEMALE; IMMUNE RESPONSE; KIDNEY; MALE; MAXIMUM PLASMA CONCENTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RHEUMATOID ARTHRITIS; SINGLE DRUG DOSE; SURVIVAL TIME; SYSTEMIC MYCOSIS; TREATMENT PLANNING;

ANIMALS; ANTIBODIES; DISEASE MODELS, ANIMAL; INFLAMMATION; MICE; MICE, INBRED C57BL; MYCOSES; OSTEOPONTIN; SIGNAL TRANSDUCTION; SYNOVIAL MEMBRANE;

EID: 50949133713     PISSN: 15675769     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.intimp.2008.06.001     Document Type: Article

References (27)

1. Buchan G., Barrett K., Turner M., Chantry D., Maini R.N., and Feldmann M. Interleukin-1 and tumor necrosis factor mRNA expression in rheumatoid arthritis: prolonged production of IL-1α. Clin Exp Immunol 73 (1988) 449-455
2. Ohshima S., Kobayashi H., Yamaguchi N., Nishioka K., Umeshita-Sasai M., Mima T., et al. Expression of osteopontin at sites of bone erosion in a murine experimental arthritis model of collagen-induced arthritis: possible involvement of osteopontin in bone destruction in arthritis. Arthritis Rheum 46 (2002) 1094-1101
3. P.K. Petrow, K.M. Hummel, J. Schedel, J.K. Franz, C.L. Klein, U.M. Ladner, et al., Expression of osteopontin messenger RNA and protein in rheumatoid arthritis: effects of osteopontin on the release of collagenase 1 from articular chondrocytes and synovial fibroblasts. Arthritis Rheum. 200;43:1539-1605.
4. Thorbecke G.J., Shah R., Leu C.H., Kuruvilla A.P., Hardison A.M., and Palladino M.A. Involvement of endogenous tumor necrosis factor-a and transforming growth factor-α during induction of collagen type II arthritis in mice. Proc Natl Acad Sci U S A 89 (1992) 7375-7379
5. Ashkar S., Weber G.F., Panoutsakopoulou V., Sanchirico M.E., Jansson M., Zawaideh S., et al. Eta-1 (osteopontin): an early component of type-1 (cell-mediated) immunity. Science 287 (2000) 860-864
6. Camussi G., Albano E., Tetta C., and Bussolino F. The molecular action of tumor necrosis factor-alpha. Eur J Biochem 202 (1991) 3-14
7. Denhardt D.T., Giachelli C.M., and Rittling S.R. Role of osteopontin in cellular signaling and toxicant injury. Annu Rev Pharmacol Toxicol 41 (2001) 723-749
8. Nau G.J., Liaw L., Chupp G.L., Berman J.S., Hogan B.L., and Young R.A. Attenuated host resistance against Mycobacterium bovis BCG infection in mice lacking osteopontin. Infect Immun 67 (1999) 4223-4230
9. O'Regan A.W., Hayden J.M., Body S., Liaw L., Mulligan N., Goetschkes M., et al. Abnormal pulmonary granulomas formation in osteopontin-deficient mice. Am J Respir Crit Care Med 164 (2001) 2243-2247
10. Shanahan J.C., and Clair E.W.S. Tumor necrosis factor-α blockade: a novel therapy for rheumatic disease. Clin Immuno 103 (2002) 231-242
11. Food and Drug Administration Center for Biologics Evaluation and Research. Safety update on TNF-α antagonists: infliximab and etanercept (2001)
12. Hyrich K.L., Silman A.J., Watson K.D., and Symmons D.P. Anti-tumour necrosis factor α therapy in rheumatoid arthritis: an update on safety. Ann Rheum Dis 63 (2004) 1538-1543
13. Wallis R.S., Broder M.S., Wong J.Y., Hanson M.E., and Beenhouwer D.O. Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin Infect Dis 38 (2004) 1261-1265
14. Yumoto K., Ishijima M., Rittling S.R., Tsuji K., Tsuchiya Y., Kon S., et al. Osteopontin deficiency protects joints against destruction in anti-type II collagen antibody-induced arthritis in mice. Proc Natl Acad Sci U S A 99 (2002) 4556-4561
15. Yamamoto N., Sakai F., Kon S., Morimoto J., Kimura C., Yamazaki H., et al. Essential role of the cryptic epitope SLAYGLR within osteopontin in a murine model of rheumatoid arthritis. J Clin Invest 112 (2003) 181-188
16. Libra M., Indelicato M., De Re V., Zignego A.L., Chiocchetti A., Malaponte G., et al. Elevated serum levels of osteopontin in HCV-associated lymphoproliferative disorders. Cancer Biol Ther 4 (2005) 1192-1194
17. Maeno Y., Nakazawa S., Yamamoto N., Shinzato M., Nagashima S., Tanaka K., et al. Osteopontin participates in Th1-mediated host resistance against nonlethal malaria parasite Plasmodium chabaudi chabaudi infection in mice. Infect Immun 74 4 (2006) 2423-2427
18. Rollo E.E., Hempson S.J., Bansal A., Tsao E., Habib I., Rittling S.R., et al. The cytokine osteopontin modulates the severity of rotavirus diarrhea. J Virol 79 (2005) 3509-3516
19. Sato I., Yamamoto N., Yamazaki H., Hashimoto S., Hino M., Sakai F., et al. Prevention of the cryptic epitope SLAYGLR within osteopontin does not influence susceptibility to Candida albicans infection. Antimicrob Agents Chemother 49 (2005) 3053-3055
20. Diao H., Kon S., Iwabuchi K., Kimura C., Morimoto J., Ito D., et al. Osteopontin as a mediator of NKT cell function in T cell-mediated liver diseases. Immunity 21 (2004) 539-550
21. Ikeda F., Wakai Y., Matsumoto S., Maki K., Watabe E., Tawara S., et al. Efficacy of FK463, a new lipopeptide antifungal agent, in mouse models of disseminated candidiasis and aspergillosis. Antimicrob Agents Chemother 44 (2000) 614-618
22. Abruzzo G.K., Flattery A.M., Gill C.J., Kong L., Smith J.G., Pikounis V.B., et al. Evaluation of the echinocandin antifungal MK-0991 (L-743,872): efficacies in mouse models of disseminated aspergillosis, candidiasis, and cryptococcosis. Antimicrob Agents Chemother 41 (1997) 2333-2338
23. Koguchi Y., Kawakami K., Uezu K., Fukushima K., Kon S., Maeda M., et al. High plasma osteopontin level and its relationship with IL-12-mediated Th1 response in tuberculosis. Am J Respir Crit Care Med 15 (2003) 1355-1359
24. Nau G.J., Chupp G.L., Emile J.F., Jouanguy E., Berman J.S., Casanova J.L., et al. Osteopontin expression correlates with clinical outcome in patients with mycobacterial infection. Am J Pathol 157 (2000) 37-42
25. Denhardt D.T., Lopez C.A., Rollo E.E., Hwang S.M., An X.R., and Walther S.E. Osteopontin-induced modifications of cellular functions. Ann N Y Acad Sci 760 (1995) 127-142
26. Chan J., Xing Y., Magliozzo R.S., and Bloom B.R. Killing of virulent Mycobacterium tuberculosis by reactive nitrogen intermediates produced by activated murine macrophages. J Exp Med 175 (1992) 1111-1122
27. Schellings M.W.M., Pinto Y.M., and Heymans S. Matricellular proteins in the heart: possible role during stress and remodeling. Cardiovascular Res 64 (2004) 24-31